The Efficacy and Safety of Azovudine in the Treatment of COVID-19

NCT05675761 | Unknown

• 1 other identifier: Innovation-A
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a prospective, multicenter clinical study. It is intended to discuss the efficacy of starting Azovudine treatment as early as possible for all types of patients of COVID-19, the time of remission of specific symptoms, the proportion of patients with severe diseases, oxygen and conditions, and related adverse reactions, so as to understand the efficacy and safety of Azovudine treatment in all types of COVID-19, and provide real world data support for the treatment of the majority of COVID-19 patients.

Conditions

COVID-19; Infections; Morality; Death, Assisted

Outcome Measures

Primary Outcomes (2)

• Continuous recovery time of clinical symptoms of Azovudine in the treatment of COVID-19

  Continuous recovery time of clinical symptoms of Azovudine in the treatment of COVID-19

  Day 1 to 28 days

• Safety evaluation results: for example, AE (adverse events) and SAE (serious adverse events) up to the 28th day

  Safety evaluation results: for example, AE (adverse events) and SAE (serious adverse events) up to the 28th dayof Novel Coronavirus Infection by the National Health Commission (Trial Version 9) The development from asymptomatic to mild/general-type The development from mild to general-type/severe type The development from general-type to severe/critical type The development from severe to critical type

  Up to 28 days

Secondary Outcomes (1)

• Evaluation of positive rate

  Day 1 to 28 days

Study Arms (2)

Combined bacterial and fungal infection

Combined bacterial and fungal infection

Drug: Azorubine

No bacterial and fungal infection

No bacterial and fungal infection

Drug: Azorubine

Interventions

Azorubine DRUG

Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)

Also known as: basic treatment

Combined bacterial and fungal infection; No bacterial and fungal infection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with novel coronavirus infection meeting the criteria of The New Coronavirus Pneumonia Diagnosis and Treatment Program (Ninth Edition)

You may qualify if:

• Over 18 years old;
• Respiratory tract samples (nasopharynx, oropharynx, lower respiratory tract \[such as sputum\]) collected within 96 hours before enrollment were confirmed to be SARS CoV-2 positive by RT-PCR virus molecular amplification;
• At least one symptom or sign of COVID-19 (symptoms and signs related to COVID-19, including cough, expectoration, dyspnea, fever, chills, fatigue, muscle soreness, diarrhea, headache, sore throat, nasal congestion, runny nose, etc.);
• Participants who meet one or more of the following requirements: from the first COVID-19 symptom to the first medication ≤ 5 days;
• Agree to observe contraceptive measures during the clinical trial;
• Participants who understand and agree to follow the planned research procedures;
• Provide follow-up information during the study;
• Understand the study and be willing to sign the informed consent form.

You may not qualify if:

• Those who are known to be allergic to any component of the intervention preparation used in the test;
• Patients with abnormal liver function test (alanine aminotransferase and /or glutamic oxaloacetic aminotransferase exceed the upper limit of normal value by 3 times, or total bilirubin exceeds the upper limit of normal value by 2 times);
• Patients with a known history of liver disease (cirrhosis with ChildPugh grade B and C);
• Congestive heart failure within 6 months (NYHA ¾ Grade), patients with untreated symptomatic arrhythmia or myocardial infarction history;
• Individuals with malabsorption syndrome or other diseases affecting gastrointestinal absorption, and patients who need intravenous nutrition or cannot take orally or through nasogastric tube;
• Participants who have received other SARS CoV-2 monoclonal antibody therapy or antiviral therapy (including research therapy);
• Participants who received COVID-19 convalescent plasma therapy;
• Patients receiving anti HIV treatment;
• Participants who also participate in any other type of medical research or are considered to be scientifically or medically incompatible with this research;
• Participants who have participated in the intervention clinical research in the past 30 days should pass 5 half lives or 30 days, whichever is longer, if the previous research intervention has a longer half life.
• Researchers believe that the test will endanger any health and safety of participants;
• Women who are pregnant, nursing or planning to be pregnant during the study period or men whose partners plan to be pregnant during the study period;
• Unable to provide informed consent.Contacts and Locations.

Sponsors & Collaborators

• Fuzhou General Hospital: lead

Study Sites (1)

The 900th Hospital of the Joint Logistic Support Force, PLA

Fuzhou, Fujian, 350000, China

RECRUITING

MeSH Terms

Conditions

COVID-19; Infections; Suicide, Assisted

Interventions

azo rubin S

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Suicide; Self-Injurious Behavior; Behavioral Symptoms; Behavior

Study Officials

• zongyang yu, Ph.D

  The 900th Hospital of the Joint Logistic Support Force, PLA

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zongyang Yu, Ph.D

CONTACT

13509327806; yuzy527@sina.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2023
• First Posted: January 9, 2023
• Study Start: January 4, 2023
• Primary Completion: October 31, 2024
• Study Completion: October 31, 2024
• Last Updated: January 10, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)